Core Insights - Silexion Therapeutics is pioneering RNA interference (RNAi) therapies targeting KRAS-driven cancers, which are notoriously difficult to treat with traditional methods [2][3] - The lead candidate, SIL204, has shown promising preclinical results in reducing tumor growth and metastasis across various cancer types, including pancreatic, colorectal, and lung cancers [2][5] Technological Platform - Silexion's technology targets KRAS mutations at the genetic level, differing from conventional small molecule inhibitors, aiming to prevent oncogenic protein production [4] - SIL204 can target multiple KRAS mutations, which are prevalent in various cancers: approximately 90% in pancreatic cancers, 45% in colorectal cancers, and 35% in non-squamous non-small-cell lung cancers [5] Preclinical Developments - A significant milestone was reached in March 2025 with the completion of studies using orthotopic pancreatic cancer models, providing a more accurate representation of cancer progression [6] - SIL204 demonstrated notable efficacy in reducing tumor cell numbers across different pancreatic cancer cell lines, indicating a nuanced understanding of therapeutic interventions [7] Strategic Approach - Silexion focuses on two primary drug delivery methods: systemic delivery for metastatic progression and intratumoral delivery for primary tumors, collaborating with Catalent to enhance formulation and manufacturing processes [8] - The company's research extends beyond pancreatic cancer, exploring applications in colorectal and lung cancers, reflecting a comprehensive understanding of KRAS-driven malignancies [9] The Road Ahead - Silexion's development roadmap includes continued preclinical studies, toxicology and pharmacodynamic investigations, potential regulatory submissions, and plans to initiate human clinical trials in the first half of 2026 [10] - The scientific community is closely monitoring Silexion's progress, as successful outcomes could significantly impact cancer therapeutics and precision oncology [11]

Registration No. 333- As filed with the Securities and Exchange Commission on May 17, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Phio Pharmaceuticals Corp. (Exact name of registrant as specified in its charter) Delaware 45-3215903 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 11 Apex Drive, Suite 300A, PMB 2006 Marlborough, Massachusetts 01752 (508) 767-386 ...

Table of Contents Registration No. 333- As filed with the Securities and Exchange Commission on December 19, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PHIO PHARMACEUTICALS CORP. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 45-3215903 (I.R.S. Employer Identification Nu ...

Table of Contents As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PHIO PHARMACEUTICALS CORP. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 257 Simarano Drive, Suite 101 Marlborough, Massach ...

Table of Contents As filed with the Securities and Exchange Commission on April 28, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PHIO PHARMACEUTICALS CORP. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 45-3215903 (I.R.S. Employer Identification Numbe ...